A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very Severe Alopecia Areata

    August 2024 in “ British Journal of Dermatology ”
    David Rosmarin, Neil S. Sadick, Timothy Rodgers, Edward Lain, Lawrence Osman, Stephen M. Schleicher, Adam Reich, Jacek C Szepietowski, Agnieszka Owczarczyk‐Saczonek, Wojciech Baran, Bartłomiej Kwiek, Michal Torz, Jacek Zdybski, Sohail S. Chaudhry, Zachary Lee, Heng Xu, Yi Liu, Brian Lewis, Katie Mellskog, Lucinda M Elko-Simms, Christie Fanton, Mary Tagliaferri, Jonathan Zalevsky, Charles Lynde
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Studysummary The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →